Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma - Takeaways - MDSpire

Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

  • By

  • Bhavana Bhatnagar

  • Srinivas Devarakonda

  • March 27, 2026

  • 0 min

Share

  • 1

    Cellular therapies have significantly improved outcomes for leukemia and myeloma patients, reducing reliance on toxic chemotherapy.

  • 2

    CAR-T cell therapy targeting BCMA has shown unprecedented responses in relapsed and refractory multiple myeloma but is not curative.

  • 3

    GPRC5D CAR-T therapy demonstrates superior efficacy and safety compared to BCMA CAR-T, particularly in patients with BCMA-low or -negative disease.

  • 4

    HLA-mismatched peripheral blood stem cell microtransplantation shows promising outcomes in myeloma, with lower toxicity and potential for broader accessibility.

  • 5

    Daratumumab's approval for high-risk smoldering myeloma has changed management strategies, emphasizing the need for nuanced treatment decisions.

Original Source(s)

Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

  • by Bhavana Bhatnagar, Srinivas Devarakonda

  • March 27, 2026

Related Content

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications

Molecular Pathology Insights into Hematologic Malignancies: An In-Depth Analysis of Genetic and Chromosomal Abnormalities and Their Clinical Implications

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence